D5.3 Web-based survey amongst layer 1 stakeholders

777363 – DRIVE

DEVELOPMENT OF ROBUST AND INNOVATIVE VACCINE EFFECTIVENESS

WP5 – Communication and dissemination of results

<table>
<thead>
<tr>
<th>Lead contributor</th>
<th>Jari Kirsilä (6 – THL), Miriam Levi (4 – UNIFI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="mailto:jari.kirsila@thl.fi">jari.kirsila@thl.fi</a>, <a href="mailto:miriam.levi@unifi.it">miriam.levi@unifi.it</a></td>
</tr>
<tr>
<td>Other contributors</td>
<td>Topi Turunen (1 – FISABIO)</td>
</tr>
<tr>
<td></td>
<td>Caterina Rizzo (7 – ISS)</td>
</tr>
<tr>
<td></td>
<td>Sam Rosoman (9 – COMO)</td>
</tr>
<tr>
<td></td>
<td>Laurence Pagnon (12 – SP)</td>
</tr>
<tr>
<td></td>
<td>Sharon McHale (14 – SEQIRUS)</td>
</tr>
</tbody>
</table>

| Due date                      | 31 Dec 2017                                      |
| Delivery date                 | 23 Dec 2017                                      |
| Deliverable type              | R                                                |
| Dissemination level           | PU                                               |

<table>
<thead>
<tr>
<th>Description of Work</th>
<th>Version</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>V0.0</td>
<td>01 Dec 2017</td>
</tr>
</tbody>
</table>
Document History

<table>
<thead>
<tr>
<th>Version</th>
<th>Date</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>V0.0</td>
<td>01 Dec 2017</td>
<td>Outline</td>
</tr>
<tr>
<td>V0.1</td>
<td>05 Dec 2017</td>
<td>First Draft</td>
</tr>
<tr>
<td></td>
<td>19 Dec 2017</td>
<td>Comments by SC</td>
</tr>
<tr>
<td>V0.2</td>
<td>22 Dec 2017</td>
<td>Final version</td>
</tr>
</tbody>
</table>

Abbreviations

CDC = Centers for Disease Control and Prevention
DRIVE = Development of Robust and Innovative Vaccine Effectiveness
ECDC = European Centre for Disease Prevention and Control
EFPIA = European Federation of Pharmaceutical Industries and Associations
EMA = European Medicines Agency
EU = European Union
FISABIO = Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana
GA = Grant Agreement
IMI = Innovative Medicines Initiative
ISC = Independent Scientific Committee
IVE = Influenza Vaccine Effectiveness
KOM = Kick-off meeting
KPI = Key Performance Indicator
NITAG = National Immunization Technical Advisory Groups
PHRB = Public Health Regulatory Body
PHI = Public Health Institute
SAGE = Strategic Advisory Group on Experts
SOP = Standard Operating Procedures
TC = Teleconference
QCAC = Quality Control and Audit Committee
WHO = World Health Organization
WP = Work Package
Publishable Summary

In order to better understand the communications needs of its stakeholders, DRIVE will carry out a web-based survey directed at the “level 1” stakeholders identified in deliverable 5.1 (Stakeholder map).

The results of the survey will advise DRIVE on topics including the content and frequency of its communications, and the best communication channels to reach its stakeholders.

Methods

A draft survey was prepared by a small working group and circulated for feedback according to the policy described in deliverable D5.2 (Agreement on communications governance model).

The relevant stakeholders and contact persons will be identified during the preparation of deliverable 5.1 (Communication of a detailed stakeholder map) and in preceding surveys sent out to public health institutes and other potential Associate Partners of DRIVE.

The target group of the survey belong to the “level 1” stakeholders of DRIVE and may include, for example, ECDC, EMA, WHO, Strategic Advisory Group on Experts (SAGE), WHO Europe, National Public Health Regulatory Bodies (PHRBs), Manufacturing Authorisation Holders (MAHs)/vaccine manufacturers, DG Santé, National Immunization Technical Advisory Groups (NITAGs) and National Public Health Institutes (NPHIs).

The survey will be administered online using the SurveyMonkey tool and may be adapted in the future based on the feedback from the stakeholders.

Annexes

Annex 1: Communications survey, questions
Annex 1: Communications survey, questions

DRIVE (Development of Robust and Innovative Vaccine Effectiveness) is a European project under the framework of the Innovative Medicines Initiative (IMI). The goal of DRIVE is to establish a sustainable platform aiming at assessing brand-specific influenza vaccine effectiveness studies in Europe.

The influenza vaccine effectiveness (IVE) results from DRIVE will be publicly disclosed through various channels including reports, peer-reviewed publications, conferences, and through a dedicated website and social media. This survey aims to understand the communication needs and expectations of DRIVE’s stakeholders and establish how DRIVE could make its results timely and broadly disseminated.

This survey is intended for experts responsible or involved in the communication of influenza-related information.

All information collected will be anonymized or pseudo-anonymized and kept in strict confidence among partners within DRIVE consortium and not shared outside of DRIVE without your consent.

1. Please provide your contact details:
   Name _____
   Organization _____
   What is the extent of influence of your organization?
   o National
   o Regional
   o Local
   o Other (please specify)________________
   Position _____
   Address _____
   Email _____
   Telephone _____

2. Does your organization have a role in communicating information related to influenza surveillance and/or influenza vaccines in your area?
   o Yes, we are the main organization responsible.
   o Yes, we share the task with other organizations (please indicate who) _____
   o No (please indicate who is responsible) _____

3. Please describe your personal role in this communication. Alternatively, please provide contact details of the person responsible for this communication: _____

4. Which of the following local stakeholders does your institution regularly communicate influenza vaccine related information to? (please select all that apply)
   - Social and health care professionals (Please specify names and contact details of organizations)
   - Medical schools (Please specify names and contact details of the schools)
   - Nursing schools (Please specify names and contact details of the schools)
   - NGOs (Please specify names and contact details of the schools)
   - Patient groups (Please specify names and contact details of patients groups)
   - Media (Please specify)_____
4. General public
☐ Other (Please specify) _____
☐ None of the above (please provide details; e.g. is there another institution that handles the communications?) _____

5. By what means do you communicate information on influenza vaccines? (please select all that apply)
☐ Websites (Please specify)_____
☐ Publications (Please specify)_____
☐ Scientific posters at conferences
☐ Conferences (Please specify)_____
☐ Public gatherings
☐ Direct communication (e.g. email, letter, face to face meeting) (Please specify the target groups of such communication)_____
☐ Media releases (Please specify)_____
☐ Social media (Please specify)_____
☐ Other (please specify) ______

6. Do you communicate on the burden of influenza illness?
☐ Yes
☐ No

7. Do you communicate on the benefits of influenza vaccines in general?
☐ Yes
☐ No

8. Do you communicate on influenza vaccine effectiveness (IVE) results in particular?
☐ Yes
☐ No

9. If yes, at what stage (s) of the influenza season do you time your communications? _____

10. What are your sources of information about influenza and/or IVE? (Please select all that apply) _________
☐ ECDC
☐ World Health Organization
☐ Ministry of Health____
☐ European Medicines Agency
☐ National Medicines Agency
☐ Scientific literature
☐ Other (Please specify)_____ 

11. Is your currently available information on IVE adequate for your needs?
☐ Yes
☐ No

12. If not, what additional information on IVE would you require? (e.g. IVE in certain area, in certain age / risk groups, of different vaccine type or brands…)
☐ IVE in certain areas
☐ IVE in certain age/risk groups
☐ IVE of different vaccine type
☐ IVE of different vaccine brands
☐ Other (Please specify)____
13. In addition to scientific conferences, peer-reviewed publications and the DRIVE website, what other means of communications would you like DRIVE to use to communicate IVE results? (please select all that apply)
- Scientific posters at conferences
- Public gatherings (Please specify)_____
- Direct communication (e.g. email, letter, face to face meeting) (Please specify the target groups of such communication)_____
- Media releases (Please specify the media)_____
- Social media (Please specify)_____
- Other (please specify)_____

14. In what format would you like to receive the results regarding vaccine effectiveness, including the brand specific data results produced by DRIVE? (please select all that apply)
- Extensive reports with detailed numerical information and discussions of results
- Condensed and easy to digest abstracts
- Infographics
- Other, please specify_____

15. What is your preferred frequency of communications from DRIVE?
- Yearly, in-depth reports of influenza vaccine effectiveness and DRIVE activities (please provide any specific requests)_____
- More frequent communications regarding influenza vaccine effectiveness and DRIVE activities; for example using a newsletter (please provide any specific requests)_____
- Other, please specify_____

16. Which of the following options would you consider using to communicate DRIVE’s results to your stakeholders? (please select all that apply)
- Websites (Please specify)_____
- Publications (Please specify)_____
- Scientific posters at conferences
- Conferences (Please specify)_____
- Public gatherings (Please specify)_____
- Direct communication (e.g. email, letter, face to face meeting) (Please specify the target communication groups)_____
- Media releases (Please specify the media)_____
- Social media (Please specify)_____
- Other (please specify)_____
- No, we would likely not communicate DRIVE’s results further (please specify the reasons)_____

17. Do you have any particular concerns about the communication of influenza vaccine effectiveness from DRIVE?
  - Yes
  - No

18. If you replied “Yes” to question 17, what are your concerns?___________________________
19. If you replied “Yes” to question 17, what could be done to address these concerns?

____________

20. If you have any additional comments, please feel free to write them here_____________________

21. Do you consent for de-identified and consolidated results from this survey to be shared outside of DRIVE?
   o Yes
   o No
   o Please provide any specific request you might have____________________________